Peptomyc was founded in 2014 as a spin-off supported by the Vall d'Hebron Institute of Oncology (VHIO) and Icrea and is based in Barcelona. The company is developing Omomyc, a biologic designed to inhibit the oncogene Myc, which its cofounder Laura Soucek has studied for decades. Peptomyc completed an initial clinical trial in patients with solid tumors and is currently running studies targeting pancreatic cancer and osteosarcoma. The recent €5 million financing will fund completion of those clinical programs. The company has indicated it may pursue a partnership with a pharmaceutical firm to accelerate development and commercialization. Public and institutional backers such as CDTI and the EIC Fund are among its current supporters.

Total raised

$26M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2026